A new approach to anesthesia management in myasthenia gravis: reversal of neuromuscular blockade by sugammadex

被引：17
作者：
de Boer, H. D. [1 ]
van Egmond, J. [2 ]
Driessen, J. J. [2 ]
Booij, L. H. J. D. [2 ]
机构：
[1] Martini Gen Hosp Groningen, Dept Anesthesiol & Pain Med, POB 30033, NL-9700 RM Groningen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept Anesthesiol Pain & Palliat Med, Nijmegen, Netherlands
来源：
REVISTA ESPANOLA DE ANESTESIOLOGIA Y REANIMACION | 2010年 / 57卷 / 03期
关键词：
Myasthenia gravis; Sugammadex; Rocuronium; Neuromuscular blockade; Reversal drug;
D O I：
10.1016/S0034-9356(10)70194-8
中图分类号：
R614 [麻醉学];
学科分类号：
100217 ;
摘要：
A neuromuscular blocking drug (NMBD) induced neuromuscular blockade (NMB) in patients with myasthenia gravis usually dissipates either spontaneously or by administration of neostigmine. We administered sugammadex to a patient with myasthenia gravis to reverse a rocuronium-induced profound NMB. NMBDs predispose such patients to severe postoperative residual paralysis and respiratory complications. Sugammadex binds steroidal NMBDs and, therefore reverses a rocuronium or vecuronium-induced NMB, without interfering with cholinergic transmission. A rapid and complete recovery from profound NMB was achieved and no adverse events were observed. This case suggests that sugammadex is a safe and effective antagonist of a rocuronium induced NMB blockade in patients with myasthenia gravis.
引用
收藏
页码：181 / 184
页数：4
相关论文
共 13 条
  • [1] Impact of anesthesia management characteristics on severe morbidity and mortality
    Arbous, MS
    Meursing, AEE
    van Kleef, JW
    de Lange, JJ
    Spoormans, HHAJM
    Touw, P
    Werner, FM
    Grobbee, DE
    [J]. ANESTHESIOLOGY, 2005, 102 (02) : 257 - 268
  • [2] Is recovery of neuromuscular transmission complete after the use of neostigmine to antagonize block produced by rocuronium, vecuronium, atracurium and pancuronium?
    Baurain, MJ
    Hoton, F
    DHollander, AA
    Cantraine, FR
    [J]. BRITISH JOURNAL OF ANAESTHESIA, 1996, 77 (04) : 496 - 499
  • [3] Bom A, 2002, ANGEW CHEM INT EDIT, V41, P266
  • [4] Briggs Edward D, 2003, J Anesth, V17, P177
  • [5] Neuromuscular transmission: New concepts and agents
    de Boer, Hans D.
    [J]. JOURNAL OF CRITICAL CARE, 2009, 24 (01) : 36 - 42
  • [6] Anesthesia issues in the perioperative management of myasthenia gravis
    Dillon, FX
    [J]. SEMINARS IN NEUROLOGY, 2004, 24 (01) : 83 - 94
  • [7] Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision
    Fuchs-Buder, T.
    Claudius, C.
    Skovgaard, L. T.
    Eriksson, L. I.
    Mirakhur, R. K.
    Viby-Mogensen, J.
    [J]. ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2007, 51 (07) : 789 - 808
  • [8] First human exposure of org 25969, a novel agent to reverse the action of rocuronium bromide
    Gijsenbergh, F
    Ramael, S
    Houwing, N
    van Iersel, T
    [J]. ANESTHESIOLOGY, 2005, 103 (04) : 695 - 703
  • [9] Neuromuscular junction in health and disease
    Hirsch, N. P.
    [J]. BRITISH JOURNAL OF ANAESTHESIA, 2007, 99 (01) : 132 - 138
  • [10] Comparative use of muscle relaxants and their reversal in three European countries: A survey in France, Germany and Great Britain
    Osmer, C
    Vogele, C
    Zickmann, B
    Hempelmann, G
    [J]. EUROPEAN JOURNAL OF ANAESTHESIOLOGY, 1996, 13 (04) : 389 - 399
12